<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00161486</url>
  </required_header>
  <id_info>
    <org_study_id>03-9401-B</org_study_id>
    <secondary_id>U 54 HD42454</secondary_id>
    <nct_id>NCT00161486</nct_id>
  </id_info>
  <brief_title>The Effects of Testosterone on Prostate Tissue (ACYP-1)</brief_title>
  <acronym>ACYP-1</acronym>
  <official_title>The Effects of Testosterone on Prostate Tissue in Normal Men (ACYP-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to understand the effects of testosterone on the
      prostate. This knowledge will be used to help in the development of a safe male hormonal
      contraceptive and may impact the development of androgen replacement therapy in older men.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will be administering two drugs: Testim (testosterone gel) and Acyline. Acyline is an
      experimental drug. We want to see their effects on levels of hormones in the blood and
      prostate. In addition, we will be examining the effects of these drugs on the expression of
      genes within the prostate.

      Acyline suppresses LH and FSH, which are hormones made by the pituitary gland, thus blocking
      the signal from the brain that causes the testes to make testosterone. Therefore, Acyline
      blocks testosterone production. In preliminary studies, a single injection of Acyline
      reversibly lowered the FSH, LH and testosterone levels in the blood for approximately 15
      days. Prolonged low levels of LH and FSH cause suppression of sperm production in normal men.
      However, men may experience some side effects from the low levels of testosterone caused by
      acyline, thus exogenous testosterone is required to sustain normal male androgen and organ
      effects without suppressing spermatogenesis. This combination of drugs is a promising male
      contraceptive regimen. In addition, millions of older men are using testosterone replacement
      to treat male &quot;andropause&quot;; low level testosterone associated with aging. However, the effect
      of testosterone on the prostate is unknown. Studies examining the effect of testosterone on
      the prostate are needed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intervention trial to examine the hormonal regulation of prostate gene expression and tissue hormone levels, tissue protein expression and apoptosis.</measure>
    <time_frame>28-days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular immune function</measure>
    <time_frame>28-days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo acyline injections every two weeks (2 doses) + placebo testosterone gel daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline 300 μg/kg every two weeks (2 doses) + placebo Testosterone gel daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks + Testosterone gel 100 mg daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone gel</intervention_name>
    <description>Testosterone gel 100 mg daily for 4 weeks</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Testim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acyline</intervention_name>
    <description>Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo acyline</intervention_name>
    <description>Placebo acyline injections every two weeks (2 doses)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Testosterone gel</intervention_name>
    <description>placebo testosterone gel daily for 4 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 35 and 55, normal serum testosterone levels, normal gonadal function

        Exclusion Criteria:

          -  History of prostate cancer, PSA&gt;2.0, AUA BPH symptom score &gt;10, History of
             testosterone or anabolic steroid use, chronic medical illness or prostate disease,
             active serious infection or immunosuppression, history of a bleeding disorder or need
             for anticoagulation, abnormal digital rectal exam, abnormal prostate ultrasound, first
             degree relative with history of prostate cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William J Bremner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>http://depts.washington.edu/popctr</description>
  </link>
  <reference>
    <citation>Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl. 2003 May-Jun;24(3):299-311. Review.</citation>
    <PMID>12721204</PMID>
  </reference>
  <reference>
    <citation>Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA. 1996 Dec 18;276(23):1904-6.</citation>
    <PMID>8968017</PMID>
  </reference>
  <reference>
    <citation>Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M. High-grade prostate cancer is associated with low serum testosterone levels. Prostate. 2001 Apr;47(1):52-8.</citation>
    <PMID>11304729</PMID>
  </reference>
  <reference>
    <citation>Nelson PS, Clegg N, Arnold H, Ferguson C, Bonham M, White J, Hood L, Lin B. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11890-5. Epub 2002 Aug 16.</citation>
    <PMID>12185249</PMID>
  </reference>
  <reference>
    <citation>Herbst KL, Anawalt BD, Amory JK, Bremner WJ. Acyline: the first study in humans of a potent, new gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab. 2002 Jul;87(7):3215-20.</citation>
    <PMID>12107227</PMID>
  </reference>
  <reference>
    <citation>Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ. Comparison of a gonadotropin releasing-hormone antagonist plus testosterone (T) versus T alone as potential male contraceptive regimens. J Clin Endocrinol Metab. 1993 Aug;77(2):427-32.</citation>
    <PMID>8345047</PMID>
  </reference>
  <reference>
    <citation>Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone. J Clin Endocrinol Metab. 1998 Oct;83(10):3527-33.</citation>
    <PMID>9768659</PMID>
  </reference>
  <reference>
    <citation>Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol RZ, Rivier J, Vale W, Swerdloff RS. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J Clin Endocrinol Metab. 1992 Aug;75(2):476-83.</citation>
    <PMID>1639948</PMID>
  </reference>
  <results_reference>
    <citation>Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, Amory JK, Nelson PS, Wu JD. Effect of medical castration on CD4+ CD25+ T cells, CD8+ T cell IFN-gamma expression, and NK cells: a physiological role for testosterone and/or its metabolites. Am J Physiol Endocrinol Metab. 2006 May;290(5):E856-63. Epub 2005 Dec 13.</citation>
    <PMID>16352669</PMID>
  </results_reference>
  <results_reference>
    <citation>Page ST, Lin DW, Mostaghel EA, Hess DL, True LD, Amory JK, Nelson PS, Matsumoto AM, Bremner WJ. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006 Oct;91(10):3850-6. Epub 2006 Aug 1.</citation>
    <PMID>16882745</PMID>
  </results_reference>
  <results_reference>
    <citation>Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, Bremner WJ, Gleave ME, Nelson PS. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007 May 15;67(10):5033-41.</citation>
    <PMID>17510436</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>September 18, 2008</last_update_submitted>
  <last_update_submitted_qc>September 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>William J Bremner, MD, PhD</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Male contraception</keyword>
  <keyword>Prostate</keyword>
  <keyword>Acyline</keyword>
  <keyword>Androgen replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

